Skip to content

Study · Non-randomized trial · n = 5 · 2015

6 results

Direct comparison of the effects of intravenous kisspeptin-10, kisspeptin-54 and GnRH on gonadotrophin secretion in healthy men.

Jayasena CN, Abbara A, Narayanaswamy S, Comninos AN, Ratnasabapathy R, Bassett P, Mogford JT, Malik Z, Calley J, Ghatei MA, Bloom SR, Dhillo WS

Human reproduction (Oxford, England)18 Jun 2015Cited by 35 (Europe PMC)

PMID26089302 (opens in a new tab)PMCIDPMC4507333 (opens in a new tab)DOI10.1093/humrep/dev143 (opens in a new tab)PepBankPUB-26089302
Download PDFPubMedAsk about this study
Jump to 6 results

Summary

Study questionHow potently does the novel hypothalamic stimulator of reproduction, kisspeptin, increase gonadotrophin secretion when compared with GnRH in healthy men?Summary answerAt the doses tested, intravenous administration of either of two major kisspeptin isoforms, kisspeptin-10 and -54, was associated with similar levels of gonadotrophin secretion in healthy men; however, GnRH was more potent when compared with either kisspeptin isoform.What is known alreadyKisspeptin-10 and -54 are naturally occurring hormones in the kisspeptin peptide family which potently stimulates endogenous GnRH secretion from the hypothalamus, so have the potential to treat patients with reproductive disorders. Rodent studies suggest that kisspeptin-54 is more potent when compared with kisspepitn-10; however, their effects have not previously been directly compared in humans, or compared with direct pituitary stimulation of gonadotrophin secretion using GnRH.Study design, size and durationA single-blinded placebo controlled physiological study was performed from January to December 2013. Local ethical approval was granted, and five participants were recruited to each dosing group.Participants/materials, setting, methodsHealthy men were administered vehicle, kisspeptin-10, kisspeptin-54 and GnRH intravenously for 3 h on different study days. Each hormone was administered at 0.1, 0.3 and 1.0 nmol/kg/h doses (n = 5 subjects per group). Regular blood sampling was conducted throughout the study to measure LH and FSH. Study visits were conducted at least a week apart.Main results and the role of chanceSerum LH and FSH levels were ∼3-fold higher during GnRH infusion when compared with kisspeptin-10 and ∼2-fold higher when compared with kisspeptin-54 [mean area under the curve serum LH during infusion (in hours times international units per litre, h.IU/l): 10.81 ± 1.73, 1.0 nmol/kg/h kisspeptin-10; 14.43 ± 1.27, 1.0 nmol/kg/h kisspeptin-54; 34.06 ± 5.18, 1.0 nmol/kg/h GnRH, P < 0.001 versus kisspeptin-10, P < 0.01 versus kisspeptin-54].Limitations, reasons for cautionThis study had a small sample size.Wider implications of the findingsKisspeptin offers a novel means of stimulating the reproductive axis. Our data suggest that kisspeptin stimulates gonadotrophin secretion less potently when compared with GnRH; however, kisspeptin may stimulate gonadotrophins in a more physiological manner when compared with current therapies. Kisspeptin is emerging as a future therapeutic agent, so it is important to establish which kisspeptin hormones could be used to treat patients with infertility. Results of this study suggest that either isoform has similar effects on reproductive hormone secretion in healthy men when administered intravenously.Study funding/competing interestsThis work is funded by grants from the MRC and NIHR and is supported by the NIHR Imperial Biomedical Research Centre Funding Scheme. C.N.J. is supported by an NIHR Clinical Lectureship. A.A. is supported by Wellcome Trust Research Training Fellowships. A.N.C. is supported by Wellcome Trust Translational Medicine Training Fellowship. W.S.D. is supported by an NIHR Career Development Fellowship.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In healthy men, intravenous kisspeptin‑10 produced about 3-fold lower serum LH than GnRH.

    In plain wordsIn healthy men, kisspeptin‑10 raised LH about 3 times less than GnRH did.

    Peptide
    Kisspeptin-10
    Outcome
    DecreaseSerum LH with kisspeptin-10 versus GnRH
    Study

    n = 5

    Comparator
    GnRH
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.1, 0.3 and 1.0 nmol/kg/h · intravenous · 3 h infusionAs given in this study (human).

    Measurements

    LH area under the curve
    10.81 h.IU/l
    1.0 nmol/kg/h kisspeptin-10
    LH area under the curve, GnRH
    34.06 h.IU/l
    1.0 nmol/kg/h GnRH

    Source sentences

    Summary
    Serum LH and FSH levels were ∼3-fold higher during GnRH infusion when compared with kisspeptin-10
    3 context sentences
    Summary · context
    10.81 ± 1.73, 1.0 nmol/kg/h kisspeptin-10; 14.43 ± 1.27, 1.0 nmol/kg/h kisspeptin-54; 34.06 ± 5.18, 1.0 nmol/kg/h GnRH, P < 0.001 versus kisspeptin-10
    Summary · context
    A single-blinded placebo controlled physiological study was performed from January to December 2013.
    Summary · context
    Healthy men were administered vehicle, kisspeptin-10, kisspeptin-54 and GnRH intravenously for 3 h on different study days. Each hormone was administered at 0.1, 0.3 and 1.0 nmol/kg/h doses (n = 5 subjects per group).
  2. 02HumanNon-randomized trialEfficacy outcome

    In healthy men, intravenous kisspeptin‑10 produced about 3-fold lower serum FSH than GnRH.

    In plain wordsIn healthy men, kisspeptin‑10 raised FSH about 3 times less than GnRH did.

    Peptide
    Kisspeptin-10
    Outcome
    DecreaseSerum FSH with kisspeptin-10 versus GnRH
    Study

    n = 5

    Comparator
    GnRH
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.1, 0.3 and 1.0 nmol/kg/h · intravenous · 3 h infusionAs given in this study (human).

    Source sentences

    Summary
    Serum LH and FSH levels were ∼3-fold higher during GnRH infusion when compared with kisspeptin-10
    2 context sentences
    Summary · context
    A single-blinded placebo controlled physiological study was performed from January to December 2013.
    Summary · context
    Healthy men were administered vehicle, kisspeptin-10, kisspeptin-54 and GnRH intravenously for 3 h on different study days. Each hormone was administered at 0.1, 0.3 and 1.0 nmol/kg/h doses (n = 5 subjects per group).
  3. 03HumanNon-randomized trialEfficacy outcome

    In healthy men, intravenous kisspeptin‑10 and kisspeptin-54 were associated with similar levels of gonadotrophin secretion.

    In plain wordsIn healthy men, kisspeptin‑10 and kisspeptin-54 given by infusion raised gonadotrophin hormones to a similar level.

    Peptide
    Kisspeptin-10
    Outcome
    No significant changeGonadotrophin secretion with kisspeptin-10 versus kisspeptin-54
    Study

    n = 5

    Comparator
    Kisspeptin-54
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.1, 0.3 and 1.0 nmol/kg/h · intravenous · 3 h infusionAs given in this study (human).

    Source sentences

    Summary
    At the doses tested, intravenous administration of either of two major kisspeptin isoforms, kisspeptin-10 and -54, was associated with similar levels of gonadotrophin secretion in healthy men; however, GnRH was more potent when compared with either kisspeptin isoform.
    3 context sentences
    Summary · context
    Results of this study suggest that either isoform has similar effects on reproductive hormone secretion in healthy men when administered intravenously.
    Summary · context
    A single-blinded placebo controlled physiological study was performed from January to December 2013.
    Summary · context
    Healthy men were administered vehicle, kisspeptin-10, kisspeptin-54 and GnRH intravenously for 3 h on different study days. Each hormone was administered at 0.1, 0.3 and 1.0 nmol/kg/h doses (n = 5 subjects per group).
  4. 04HumanNon-randomized trialEfficacy outcome

    In healthy men, serum LH during kisspeptin‑54 infusion was about 2-fold lower than during GnRH infusion.

    In plain wordsIn healthy men, LH was about two times higher during GnRH infusion than during kisspeptin‑54 infusion.

    Peptide
    Kisspeptin-54 (metastin)
    Outcome
    DecreaseSerum LH versus GnRH infusion
    Study

    n = 5

    Comparator
    GnRH
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    1.0 nmol/kg/h · intravenous · 3 h infusionAs given in this study (human).

    Measurements

    Mean serum LH AUC
    14.43 h.IU/l
    kisspeptin-54 1.0 nmol/kg/h
    Mean serum LH AUC
    34.06 h.IU/l
    GnRH 1.0 nmol/kg/h

    Source sentences

    Summary
    Serum LH and FSH levels were ∼3-fold higher during GnRH infusion when compared with kisspeptin-10 and ∼2-fold higher when compared with kisspeptin-54 [mean area under the curve serum LH during infusion (in hours times international units per litre, h.IU/l): 10.81 ± 1.73, 1.0 nmol/kg/h kisspeptin-10; 14.43 ± 1.27, 1.0 nmol/kg/h kisspeptin-54; 34.06 ± 5.18, 1.0 nmol/kg/h GnRH
    2 context sentences
    Summary · context
    Healthy men were administered vehicle, kisspeptin-10, kisspeptin-54 and GnRH intravenously for 3 h on different study days.
    Summary · context
    Each hormone was administered at 0.1, 0.3 and 1.0 nmol/kg/h doses (n = 5 subjects per group).
  5. 05HumanNon-randomized trialEfficacy outcome

    In healthy men, serum FSH during kisspeptin‑54 infusion was about 2-fold lower than during GnRH infusion.

    In plain wordsIn healthy men, FSH was about two times higher during GnRH infusion than during kisspeptin‑54 infusion.

    Peptide
    Kisspeptin-54 (metastin)
    Outcome
    DecreaseSerum FSH versus GnRH infusion
    Study

    n = 5

    Comparator
    GnRH
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    0.1, 0.3 and 1.0 nmol/kg/h · intravenous · 3 h infusionAs given in this study (human).

    Source sentences

    Summary
    Serum LH and FSH levels were ∼3-fold higher during GnRH infusion when compared with kisspeptin-10 and ∼2-fold higher when compared with kisspeptin-54
    2 context sentences
    Summary · context
    Healthy men were administered vehicle, kisspeptin-10, kisspeptin-54 and GnRH intravenously for 3 h on different study days.
    Summary · context
    Each hormone was administered at 0.1, 0.3 and 1.0 nmol/kg/h doses (n = 5 subjects per group).
  6. 06HumanNon-randomized trialEfficacy outcome

    In healthy men, intravenous kisspeptin‑54 and kisspeptin-10 were associated with similar gonadotrophin secretion at the doses tested.

    In plain wordsIn healthy men, kisspeptin‑54 and kisspeptin-10 gave similar hormone release at the doses tested.

    Peptide
    Kisspeptin-54 (metastin)
    Outcome
    No significant changeGonadotrophin secretion versus kisspeptin-10
    Study

    n = 5

    Comparator
    Kisspeptin-10
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    0.1, 0.3 and 1.0 nmol/kg/h · intravenous · 3 h infusionAs given in this study (human).

    Source sentences

    Summary
    At the doses tested, intravenous administration of either of two major kisspeptin isoforms, kisspeptin-10 and -54, was associated with similar levels of gonadotrophin secretion in healthy men; however, GnRH was more potent when compared with either kisspeptin isoform.
    2 context sentences
    Summary · context
    Healthy men were administered vehicle, kisspeptin-10, kisspeptin-54 and GnRH intravenously for 3 h on different study days.
    Summary · context
    Each hormone was administered at 0.1, 0.3 and 1.0 nmol/kg/h doses (n = 5 subjects per group).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Versions 4 to 18Current

    28 Oct 2026, 02:02 UTC

    The same notice was added 15 times, first on 13 Oct 2026, 21:44 UTC. The status did not change between them.

    Study results updated

  2. Version 3

    13 Oct 2026, 16:31 UTC

    Study data updated · source update from Europe PMC

  3. Version 2

    10 Oct 2026, 09:43 UTC

    Study results updated

  4. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.